Factor H Antibody (Polyclonal)

A goat antiserum raised against human Factor H.

Product Specifications

Citations	32
Clonality	Polyclonal
Immunogen	Highly purified human Factor H
Applications	See citations and technical data sheet for application info.
Concentration	> 40 mg/mL
Conjugate	Unconjugated
Cross Reactivity	Human, Baboon, Horse, Dog, Cat, Rabbit, Hamster, Mouse, Rat, Guinea Pig

Technical Documents

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.

Catalog Number	A312
Catalog Number (CE)	N/A
Size	2.0 mL
Price (USD)	$200.00
Price (EURO)	175,00 €

Request an Order

Contact us

US Phone	+1 (858) 552 1100
EU Phone	+353 (91) 412 474
US Email	contact-us@quidelortho.com
EU Email	contact-emea@quidelortho.com

Specifications
Citations
Certificate of Analysis

Specifications

Description	A goat antiserum raised against human Factor H.
Size	2.0 mL
Concentration	> 40 mg/mL
Applications	See citations and technical data sheet for application info.
Form	Liquid. Whole Antiserum. ≤ 0.1% Sodium Azide
Clonality	Polyclonal
Immunogen	Highly purified human Factor H
Conjugate	Unconjugated
Cross Reactivity	Human, Baboon, Horse, Dog, Cat, Rabbit, Hamster, Mouse, Rat, Guinea Pig
Isotype	Goat IgG
Purity	N/A
Source	Goat
Specificity	The Anti-human Factor H polyclonal antisera was tested against normal human serum/plasma by immunodiffusion, one-dimensional immunoelectrophoresis, and rocket immunoelectrophoresis. The antisera was determined to be monospecific for Factor H at varying concentrations.
Storage	Short term (30 days) 4˚C. Long term at or below –20˚C.
Background	Factor H is a single-chain glycoprotein with a molecular weight of approximately 150 KD. The concentration of this protein in normal human plasma/serum is approximately 500 µg/mL. Factor H can regulate the complement system on both the cellular surface and in fluid phase, and plays roles in both the alternative and classical pathways of activation. Factor H regulates formation and function of C3 convertase enzyme in the alternative pathway. It binds to C3b and inhibits C3 convertase formation, dissociates assembled C3 convertase, accelerates Factor I mediated cleavage of C3b to C3bi, and hinders C5 binding to the C3b subcomponent of both the alternative and classical pathways. Factor H also regulates the spontaneous fluid-phase activation of the alternative complement pathway by C3b-like forms of C3 that continuously arise in plasma and serum. Therefore, when concentrations of Factor H fall below normal levels, rapid fluid-phase activation occurs which causes consumption of complement components both in vivo and in vitro.

Citations

Title	Year	Applications	Sample Species	Sample	Sample Details
Truncated Complement Factor H Y402 Gene Therapy Cures C3 Glomerulonephritis	2024	WB	Mouse	Plasma	C3 glomerulonephritis
Anti-factor H autoantibodies in patients with lupus nephritis	2024	WB	Human	Plasma	Lupus nephritis
Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators	2024	ELISA	Purified Protein	Bispecific antibody
Recruitment of Factor H to the Streptococcus suis Cell Surface is Multifactorial.	2016	ELISA	Bacteria	Streptococcus suis
Antigenic Variation in Streptococcus pneumoniae PspC Promotes Immune Escape in the Presence of Variant-Specific Immunity.	2018	FC	Bacteria	Streptococcus pneumoniae
Mechanism of Borrelia immune evasion by FhbA-related proteins	2022	WB	Bacteria	Borrelia hermsii
Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity	2013	WB	Cell Culture	CLL Cells
Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.	2019	ELISA	Human	Plasma
Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.	2019	ELISA	Human	Serum
Defining the Glycosaminoglycan Interactions of Complement Factor H-Related Protein 5	2021	ELISA	Human	Purified protein
Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration.	2021	ELISA	Human	Serum	Age-Related Macular Degeneration
Systemic complement levels in patients with age-related macular degeneration carrying rare or low frequency variants in the CFH gene.	2021	ELISA	Human	Plasma
Clinicopathologic Implications of Complement Genetic Variants in Kidney Transplantation.	2021	ELISA	Human	Protein	Factor H WT and Variants
The C-type lectin of the aggrecan G3 domain activates complement	2013	ELISA	Human	Purified protein
Mapping rare, deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic levels in familial AMD	2016	ELISA	Human	Purified Protein
Mapping rare, deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic levels in familial AMD	2016	ELISA	Human	Serum
Cyclosporine induces endothelial cell release of complement-activating microparticles	2013	FC	Human	Endothelial Cells	Microparticles incubation
Immune evasion by acquisition of complement inhibitors: the mould Aspergillus binds both factor H and C4b binding protein	2008	FC, IF	Human	Plasma	Aspergillus incubated
Anti-Factor H Antibody Reactivity in Young Adults Vaccinated With a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein.	2019	Hemolytic Assay	Human	Serum
ApoE Attenuates Unresolvable Inflammation by Complex Formation With Activated C1q.	2019	IF	Human	Choroid plexus Tissue
Complement Factor H Expressed by Retinal Pigment Epithelium Cells Can Suppress Neovascularization of Human Umbilical Vein Endothelial Cells: An in vitro Study	2015	IF, WB	Human	ARPE-19 cells
Activation of complement system in kidney after ketoprofen-induced kidney injury in sheep	2015	IHC	Human	Kidney Tissue
Attenuation of renal ischemia and reperfusion injury by human adrenomedullin and its binding protein	2010	WB	Human	Plasma
Resuscitation of uncontrolled traumatic hemorrhage induced by severe liver injury: the use of human adrenomedullin and adrenomedullin binding protein-1	2010	WB	Human	Plasma
Expression of complement components, receptors and regulators by human dendritic cells	2011	WB	Human	Monocyte Derived Dendritic Cell
Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis.	2020	ELISA, IF, WB	Mouse	Kidney Tissue
Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis.	2020	ELISA, IF, WB	Mouse	Plasma
Annexin A2 Enhances Complement Activation by Inhibiting Factor H	2016	ELISA, WB	Mouse	Kidney Tissue
Annexin A2 Enhances Complement Activation by Inhibiting Factor H	2016	ELISA, WB	Mouse	Plasma
Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase.	2009	WB	Mouse	Serum
Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury	2011	WB	Mouse	Serum
Regulation of C3 Activation by the Alternative Complement Pathway in the Mouse Retina	2016	WB	Mouse	Plasma
Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation	2009	ELISA	N/A	Purified protein	SLRP
Pro-inflammatory cytokines from Kupffer cells downregulate hepatocyte expression of adrenomedullin binding protein-1	2007	WB	Rat	Hepatocytes
Pro-inflammatory cytokines from Kupffer cells downregulate hepatocyte expression of adrenomedullin binding protein-1	2007	WB	Rat	Kupffer cells

Certificate of Analysis

Showing results for

No results found for